-+ 0.00%
-+ 0.00%
-+ 0.00%

Aldeyra Therapeutics Secures Fast Track Designation for ADX-2191, Initiates Phase 2/3 Trial for Retinitis Pigmentosa Treatment

Reuters·08/19/2025 11:01:22

Please log in to view news